References
- Allocati, N., Masulli, M., Alexeyev, M., F., Di Ilio, C. (2013). Escherichia coli in Europe: an overview. Int. J. Environ. Res. Public Health,10 (12), 6235–6254.
- Anonymous (2013). Antimicrobial resistance surveillance in Europe Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Available from: European Centre for Disease Prevention and Control on the World Wide Web: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf (accessed 11 March 2018).
- Anonymous (2017). CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Wayne, P.A.: Clinical and Laboratory Standards Institute. Available from: http://www.facm.ucl.ac.be/intranet/CLSI/CLSI-2017-M100-S27.pdf (accessed 24 March 2018).
- Asir, J., Nair, S., Devi, S., Prashanth, K., Saranathan, R., Kanungo, R. (2015). Simultaneous gut colonisation and infection by ESBL-producing Escherichia coli in hospitalised patients. Australas Med. J., 8 (6), 200–207.
- Birgand, G., Armand-Lefevre, L., Lolom, I., Ruppe, E., Andremont, A., Lucet, J. C. (2013). Duration of colonization by extended-spectrum beta-lactamase-producing Enterobacteriaceae after hospital discharge. Amer. J. Infect. Control., 41 (5), 443–447.
- Cantón, R., González-Alba, J. M., Galán, J. C. (2012). CTX-M enzymes: Origin and diffusion. Front. Microbiol.,3, 110.
- Caratolli, A. (2009). Resistance plasmid families in Enterobacteriaceae. Antimicrob. Agents Chemother.,53 (6), 2227–2238.
- Carlet, J. (2012). The gut is the epicentre of antibiotic resistance. Antimicrob. Resist. Infect. Control., 1, 39.
- Cohen-Nahum, K., Saidel-Odes, L., Riesenberg, K., Schlaeffer, F., Bore, A. (2010). Urinary tract infections caused by multi-drug resistant Proteus mirabilis: Risk factors and clinical outcomes. Infection,38 (1), 41–46.
- Hawser, S. P., Bouchillon, S. K., Hoban, D. J., Badal, R. E., Cantón, R., Baquero, F. (2010). Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum β-lactamases in community- and hospital-associated intra-abdominal infections in Europe: Results of the 2008 study for monitoring antimicrobial resistance trends (SMART). Antimicrob. Agents Chemother., 54 (7), 3043–3046.
- Hoffmann, H., Stürenberg, E., Husemann, J., Roggenkamp, A. (2006). Prevalence of extended-spectrum β-lactamases in isolates of the Enterobacter cloacae complex from German hospitals. Clin. Microbiol. Infect.,12 (4), 322–330.
- Idowu, O., Onipede, A., Orimolade, A., Akinyoola, L., Babalola, G. (2011). Extended-spectrum beta-lactamase orthopedic wound infections in Nigeria. J. Glob. Infect. Dis., 3 (3), 211–215.
- Jarlier V., Nicolas, M. H., Fournier, G., Philippon A. (1988). Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev. Infect. Dis., 10 (4), 867–878.
- Kliebe, C., Nies, B., Meyer, J., Tolxdorff-Neutzling, R., Wiedemann, B. (1985). Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob. Agents Chemother.,28 (2), 302–307.
- Knothe, H., Shah, P., Krcmery, V., Antal, M., Mitsuhashi, S. (1983). Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection, 11 (6), 315–317.
- Liakopoulos, A., Mevius, D., Ceccarelli, D. (2016). A review of SHV extended- spectrum β-lactamases: Neglected yet ubiquitous. Front. Microbiol., 7, 1374.
- Līduma, I. (2016). Staphyloccocus epidermidis virulence factors and epidemiological impact. (Staphylococcus epidermidis virulences faktori un epidemioloģiskā nozīme). Doctoral dissertation, University of Latvia, Rīga, Latvia.
- Luvsansharav, U., Hirai, I., Niki, M., Nakata, A., Yoshinaga, A., Yamamoto, A., Yamamoto, M., Toyoshima, H., Kawakami, F., Matsuura, N., Yamamoto, Y. (2013). Fecal carriage of CTX-M beta-lactamase-producing Enterobacteriaceae in nursing homes in the Kinki region of Japan. Infect. Drug Resist., 6, 67–70.
- Mulki, S. S., Ramamurthy, K., Bhat, S. (2017). Fecal carriage of extended- spectrum beta-lactamase-producing Enterobacteriaceae in intensive care unit patients. Indian J. Critical Care Med.,21 (8), 525–527.
- Ny, S., Löfmark, S., Börjesson, S., Englund, S., Ringman, M., Bergström, J., Nauclér, P., Giske, C. G., Byfors, S. (2017). Community carriage of ESBL-producing Escherichia coli is associated with strains of low pathogenicity: A Swedish nationwide study. J. Antimicrob. Chemother.,72 (2), 582–588.
- Paberza, R., Selderiņa, S., Leja, S., Storoženko, J., Lužbinska, L., Žileviča, A. (2007). Prevalence of extended-spectrum β-lactamase producing Enterobacteriaceae strains in Latvia. Bioautomation,7, 99–103.
- Paterson, D. L., Bonomo, R. A. (2005). Extended-spectrum β-lactamases: A clinical update. Clin. Microbiol. Rev.,18 (4), 657–686.
- Petit, A., Gerbaud, G., Sirot, D., Courvalin, P., Sirot, J. (1990). Molecular epidemiology of TEM-3 (CTX-1) beta-lactamase. Antimicrob. Agents Chemother.,34, 219–224.
- Rawat, D., Nair, D. (2010). Extended-spectrum β-lactamases in Gram negative bacteria. J. Glob. Infect. Dis., 2 (3), 263–274.
- Reuland, E., Naiemi, N., Kaiser, A., Heck, M., Kluytmans, J., Savelkoul, M., Elders, P., Vandenbroucke-Grauls, C. (2016). Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam. J. Antimicrob. Chemother., 71 (4), 1076–1082.
- Rubio-Perez, I., Martin-Perez, E., Garcia, D., Lopez-Brea Calvo, M., Barrera, E. L. (2012). Extended-spectrum beta-lactamase-producing bacteria in a tertiary care hospital in Madrid: Epidemiology, risk factors and antimicrobial susceptibility patterns. Emerg. Health Threats J., 5, 10.
- Schoevaerdts, D., Verroken, A., Huang, T., Frennet, M., Berhin, C., Jamart, J., Bogaerts, P., Swine, C., Glupczynski, Y. (2012). Multidrug-resistant bacteria colonization amongst patients newly admitted to a geriatric unit: a prospective cohort study. J. Infect., 65 (2), 109–118.
- Shaikh, S., Fatima, J., Shakil, S., Rizvi, S., Kamal, M. (2015). Risk factors for acquisition of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae in North-Indian hospitals. Saudi J. Biol. Sci., 22 (1), 37–41.
- Sharif, M. R., Soltani, B., Moravveji, A., Erami, M., Soltani, N. (2016). Prevalence and risk factors associated with extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae isolates in hospitalized patients in Kashan (Iran). Electron. Physician,8 (3), 2081–2087.
- Sibhghatulla, S., Jamale, F., Shazi S., Syed, M., Danish, R., Mohammad, A. K. (2015). Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. Saudi J. Biol. Sci., 22 (1), 90–101.
- Skuja, V., Viksna, L., Kigitovica, D., Derovs, A., Pekarska, K., Caune, U., Piekuse, L., Kempa, I., Rudzite, D., Lejnieks, A., Krumina, A. (2015). Digestive system diseases as the most common disease group among patients with extended-spectrum beta-lactamase producing bacterial infection. In: Research Articles in Medicine & Pharmacy. Rīga Stradiņš University,Rīga, pp. 5–16.
- Spanu, T., Sanguinetti, M., Ciccaglione, D., D Inzeo, T., Romano, L., Leone, F., Fadda, G. (2003). Use of the VITEK 2 system for rapid identification of clinical isolates of staphylococci from bloodstream infections. J. Clin. Microbiol., 41 (9), 4259–4263.
- Tängdén, T., Cars, O., Melhus, A., Löwdin, E. (2010). Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-Mtype extended-spectrum β-lactamases: a prospective study with Swedish volunteers. Antimicrob. Agents Chemother.,54 (9), 3564–3568.
- Tansarli, G., Poulikakos, P., Kapaskelis, A., Falagas, M. (2014). Proportion of extended-spectrum β-lactamase (ESBL)-producing isolates among Enterobacteriaceae in Africa: evaluation of the evidence—systematic review. J. Antimicrob. Chemother.,69, 1177–1184.
- Tham, J., Walder, M., Melander, E., Odenholt, I. (2012). Duration of colonization with extended-spectrum beta-lactamase producing Escherichia coli in patients with travellers’ diarrhoea. Scand. J. Infect. Dis.,44, 573–577.
- Willemsen, I., Oome, S., Verhulst, C., Pettersson, A., Verduin, K., Kluytmans, J. (2015). Trends in extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae and ESBL genes in a Dutch teaching hospital, measured in 5 yearly point prevalence surveys (2010–2014). PLoS ONE, 10 (11), e0141765.
- Woerther, P. L., Burdet, C., Chachaty, E., Andremont, A. Trends in human fecal carriage of extended-spectrum β-lactamases in the community: Toward the globalization of CTX-M. (2013). Clin. Microbiol. Rev.,26 (4), 744–758.
- Yasmin, T., Yusuf, A., Sayam, M., Haque, R., Mowla, G. (2015). Status of ESBL producing bacteria isolated from skin wound at a tertiary care hospital in Bangladesh. Advances in Infectious Diseases,5, 174–179.
- Zahar, J., Poirel, L., Dupont, C., Fortineau, N., Nassif, X., Nordmann, P. (2015). About the usefulness of contact precautions for carriers of extended- spectrum beta-lactamase-producing Escherichia coli. BMC Infect. Dis.,15, 512.